Comparison of Hormone Receptor Status in Primary and Recurrent Breast Cancer


avatar Hamid Saeedi Saedi 1 , avatar Mohammad-Reza Ghavam Nasir 2 , avatar Soodabeh ShahidSales 2 , * , avatar Ali Taghizadeh 2 , avatar Nama Mohammadian 2

Dept. of Radiation Oncology, Cancer Research Center, Gilan University of Medical Sciences, Rasht, Iran
Dept. of Radiation Oncology, Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

how to cite: Saeedi Saedi H, Ghavam Nasir M, ShahidSales S , Taghizadeh A, Mohammadian N. Comparison of Hormone Receptor Status in Primary and Recurrent Breast Cancer. Int J Cancer Manag. 2012;5(2):e80803.


Background: Systematic treatments such as hormone and chemotherapy are selected according to tumor characteristic after major therapeutic approaches such as surgery. This study attempted to analyze and compare the status of Estrogen Receptor (ER) and Progesterone Receptor (PR) in primary and recurrent sites of breast cancer in patients.
Methods: We reviewed all medical records of breast cancer women who were treated between January 1995 and December 2008. One hundred eighty two out of 2241 patients (8.12%) had a metastatic breast cancer. Amongst them 48 patients had tumor and biopsy-driven samples, however 13 samples were destroyed and only 35 samples were investigated in this study, therefore 35 malignant biopsy specimens of breast cancer patients were examined by immunohistochemistry essay for ER and PR. Binominal proportional test and Chi square test were conducted to determine the significant correlation between positive cases of hormone receptors among primary and metastases sites.
Results: Hormone Receptor in the primary tumor (HR1) of 9 patients (25.7%) was positive (ER1 and/or PR1) and in the recurrent areas (HR2) of 8 patients (22.9%) was positive (either ER2 or PR2 positive). Kappa coefficients of diagnostic agreement in primary and recurrent cases were 0.077 and 0.125 for estrogen and progesterone, respectively which indicated that the amount of coefficient of agreement is not considerable between primary and recurrent sites.
Conclusion: The current study indicated that receptor status in recurrent tumors did not pose predictable value based on the analysis of hormone receptors in primary stage, so it is not an appropriate basis to set up therapeutic protocol in the metastatic patients. Therefore, tissue sampling and hormone receptor reanalyzing of metastatic sites should be considered in these cases.


Full text is available in PDF.

© 2012, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.